CoChat

Adjustment of L‐T4 substitutive therapy in pregnant women with subclinical, overt or post‐ablative hypothyroidism

Verga, Uberta, Bergamaschi, Silvia, Cortelazzi, Donatella, Ronzoni, Stefania, Marconi, Anna Maria, Beck‐Peccoz, Paolo · 2009 · Clinical Endocrinology
Cited by 56

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Summary: Objective Maternal hyperthyrotropinaemia is associated with an increased risk of adverse maternal and neonatal outcomes. Physiological changes during pregnancy require an increased production of thyroid hormones (or an increase in daily substitutive doses of L‐T 4 in hypothyroid patients) to meet the maternal and foetal needs. The aim of the study was to evaluate variations of substitutive L‐T 4 doses that are able to maintain serum TSH between 0·5 and 2·5 mU/l in pregnant women with subclinical‐ (SH), overt‐ (OH) and post‐ablative (PH) hypothyroidism. Design This was a retrospective study on hypothyroid pregnant women referred to the out‐patient department between January 2004 and December 2006. Patients and measurements A total of 185 pregnant women were studied during gestation; 155 patients (76 SH, 52 OH, 27 PH) were already on L‐T 4 before conception and 30 (SH) started L‐T 4 therapy during gestation. Thyroid function and body weight were evaluated every 4–6 weeks. Results In the group of patients already treated before conception, 134 (86·5%) increased L‐T 4 doses during gestation one or more times, eight (6%) reached a definitive therapeutic dosage within the 12th week of pregnancy, 64 (47·8%) within the 20th week and 62 (46·2%) within the 31st week. This initial L‐T 4 increase at the first evaluation during pregnancy was 22·9 ± 9·8 µg/day. The final L‐T 4 doses were significantly different depending on the aetiology, being 101·0 ± 24·6 µg/day in SH, 136·8 ± 30·4 µg/day in OH and 159·0 ± 24·6 µg/day in PH. The per cent increase of L‐T 4, expressed as Δ% of absolute dose, was +70% in SH, +45% in OH and +49% in PH as compared to baseline dose. In SH patients diagnosed during gestation, the starting L‐T 4 dose was higher than L‐T 4 dose before pregnancy of SH patients already treated (75·4 ± 14·5 and 63·2 ± 20·1 µg/day, respectively), whereas the final doses were similar. L‐T 4 dose was increased one or more times in 24 patients (80%), 8 reached the definitive dosage within the second trimester (33·3%) and 16 within the third trimester (66·7%). Conclusions Serum TSH and FT 4 measurements are mandatory in pregnant patients and the optimal timing for increasing L‐T 4 is the first trimester of pregnancy, though many patients require adjustments also during the second and third trimester. The aetiology of hypothyroidism influences the adjustment of L‐T 4 therapy and SH patients needed a larger increase than OH and PH. Close monitoring during pregnancy appears to be mandatory in hypothyroid women.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2265.2008.03398.x

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 56

Metadata

Authors
Verga, U., Bergamaschi, S., Cortelazzi, D., Ronzoni, S., Marconi, A. M., & Beck‐Peccoz, P.
Venue
Clinical Endocrinology
Publisher
Wiley
Published
2009-03-31
Volume
70
Issue
5
Pages
798-802
ISSN
  • 0300-0664 (ISSN-L)
  • 1365-2265
OpenAlex
W2031990342
Cited by
56
References
7
FWCI
2.40
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adjustment of L‐T4 substitutive therapy in pregnant women with subclinical, overt or post‐ablative hypothyroidism. https://app.cochat.ai/papers/10.1111/j.1365-2265.2008.03398.x
The paper
Verga, U., Bergamaschi, S., Cortelazzi, D., Ronzoni, S., Marconi, A. M., & Beck‐Peccoz, P. (2009). Adjustment of L‐T4 substitutive therapy in pregnant women with subclinical, overt or post‐ablative hypothyroidism. Clinical Endocrinology. https://doi.org/10.1111/j.1365-2265.2008.03398.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.